Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025 Cumulus Neuroscience unveiled pivotal findings at CTAD 2025, showcasing how at-home digital endpoints enhance trial efficiency and cost-effectiveness in Alzheimer's research.

Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025 #United_States #San_Diego #Alzheimer's_Disease #Cumulus_Neuroscience #NeuLogiq

Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences Cumulus Neuroscience has presented groundbreaking findings at prominent neuroscience events, highlighting advancements in clinical trials and digital health technology.

Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences #United_Kingdom #Clinical_Trials #Amsterdam #Cumulus_Neuroscience #NeuLogiq

Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors Cumulus Neuroscience, a leader in digital health, announces Robert Ballantine's appointment to its board, enhancing its commitment to neuroscience innovations.

Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors #United_Kingdom #Belfast #Cumulus_Neuroscience #NeuLogiq #Robert_Ballantine

Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting Cumulus Neuroscience presented pivotal data at the AD/PD 2025 Annual Meeting, validating its NeuLogiq® Platform for Alzheimer's and ALS-FTD assessments.

Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting #None #Vienna #Alzheimer's_Disease #Cumulus_Neuroscience #NeuLogiq